Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Johnson & Johnson will invest $55 billion in the U.S. over the next four years. The announcement comes a month after Eli ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

After rising to prominence during the COVID-19 pandemic, South African drugmaker Aspen Pharmacare has landed in the FDA's ...

Activist investor Sarissa Capital won control over Amarin’s board two years ago on a fierce campaign of stirring up value for ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...